These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3665819)

  • 41. Understanding the response lag to tricyclics. I. Application of pulse-loading regimens with intravenous clomipramine.
    Pollock BG; Perel JM; Shostak M; Antelman SM; Brandom B; Kupfer DJ
    Psychopharmacol Bull; 1986; 22(1):214-9. PubMed ID: 3726069
    [No Abstract]   [Full Text] [Related]  

  • 42. Release of human neurophysin I during insulin-induced hypoglycemia in depressed patients is abolished after recovery with clomipramine treatment.
    Geenen V; Langer G; Koinig G; Schönbeck G; Ansseau M; von Frenckell R; Smitz S; Legros JJ
    Psychoneuroendocrinology; 1985; 10(1):61-9. PubMed ID: 3889965
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clomipramine plasma level and clinical response.
    Broadhurst AD; James HD; Corte LD; Heeley AF
    Postgrad Med J; 1977; 53 Suppl 4():139-45. PubMed ID: 600891
    [No Abstract]   [Full Text] [Related]  

  • 44. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression?
    Castrogiovanni P; Blardi P; De Lalla A; Dell'Erba A; Auteri A
    Psychopharmacol Bull; 2003; 37(2):102-8. PubMed ID: 14566218
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical significance of plasma levels of clomipramine, its hydroxylated and desmethylated metabolites: prediction of clinical outcome in mood disorders using discriminant analysis of therapeutic drug monitoring data.
    Noguchi T; Shimoda K; Takahashi S
    J Affect Disord; 1993 Dec; 29(4):267-79. PubMed ID: 8126313
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clomipramine in the treatment of depressive syndrome: the results from the open study of Hydiphen].
    Myszka DM
    Psychiatr Pol; 1996; 30(6):1003-8. PubMed ID: 9132762
    [No Abstract]   [Full Text] [Related]  

  • 47. Clomipramine and age: an interaction study.
    Watson JU; Beaumont G; Poole P
    J Int Med Res; 1980; 8 Suppl 3():81-4. PubMed ID: 7202822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clomipramine: plasma levels and clinical effects.
    Reisby N; Gram LF; Bech P; Sihm F; Krautwald O; Elley J; Ortmann J; Christiansen J
    Commun Psychopharmacol; 1979; 3(5):341-51. PubMed ID: 548213
    [No Abstract]   [Full Text] [Related]  

  • 49. Relationships between clinical response, plasma levels and side-effects of clomipramine (Anafranil) in general practitioner trials.
    Miller P; Luscombe DK; Jones RB; Seldrup J; Beaumont G; John V
    J Int Med Res; 1977; 5(1 Suppl):108-18. PubMed ID: 863079
    [No Abstract]   [Full Text] [Related]  

  • 50. Relevance of tryptophan and tyrosine availability in endogenous and 'non-endogenous' depressives treated with imipramine or clomipramine.
    Møller SE; Reisby N; Ortmann J; Elley J; Krautwald O
    J Affect Disord; 1981 Sep; 3(3):231-44. PubMed ID: 6456290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clomipramine and doxepin in depressive neurosis. Plasma levels and therapeutic response.
    Linnoila M; Seppala T; Mattila MJ; Vihko R; Pakarinen A; Skinner T
    Arch Gen Psychiatry; 1980 Nov; 37(11):1295-9. PubMed ID: 7436691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High plasma concentrations of desmethylclomipramine after chronic administration of clomipramine to a poor metabolizer.
    Balant-Gorgia AE; Balant L; Zysset T
    Eur J Clin Pharmacol; 1987; 32(1):101-2. PubMed ID: 3582462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clomipramine by different routes of administration: short- and long-term efficacy and predictors of clinical outcome.
    Faravelli C; Pallanti S
    Psychopharmacol Bull; 1987; 23(3):459-63. PubMed ID: 3432514
    [No Abstract]   [Full Text] [Related]  

  • 54. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites.
    Balant-Gorgia AE; Balant LP; Genet C; Dayer P; Aeschlimann JM; Garrone G
    Eur J Clin Pharmacol; 1986; 31(4):449-55. PubMed ID: 2880723
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Compared plasma and brain pharmacokinetics of clomipramine and its metabolite demethylclomipramine in two strains of mice (NMRI and CD1).
    Marty H; Varoquaux O; Fialip J; Cordonnier P; Duroux E; Bulach C; Eschalier A; Advenier C; Pays M; Bastide P
    Fundam Clin Pharmacol; 1992; 6(2):49-57. PubMed ID: 1607145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Myoclonic movements as a side-effect of treatment with therapeutic doses of clomipramine.
    Casas M; Garcia-Ribera C; Alvarez E; Udina C; Queralto JM; Grau JM
    Int Clin Psychopharmacol; 1987 Oct; 2(4):333-6. PubMed ID: 3693873
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clomipramine therapy in the geriatric hospital: experience with therapeutic drug monitoring.
    Bocksberger JP; Gex-Fabry M; Gauthey L; Balant-Gorgia AE
    Ther Drug Monit; 1994 Apr; 16(2):113-9. PubMed ID: 8009557
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma levels of clomipramine and its N-desmethyl metabolite following oral administration of clomipramine in man [proceedings].
    Jones RB; Luscombe DK
    Br J Pharmacol; 1976 Jul; 57(3):430P. PubMed ID: 974329
    [No Abstract]   [Full Text] [Related]  

  • 59. Neonatal convulsions caused by withdrawal from maternal clomipramine.
    Cowe L; Lloyd DJ; Dawling S
    Br Med J (Clin Res Ed); 1982 Jun; 284(6332):1837-8. PubMed ID: 6805722
    [No Abstract]   [Full Text] [Related]  

  • 60. Clomipramine-induced pancytopenia.
    Magni G; Urbani A; Silvestro A; Grassetto M
    J Nerv Ment Dis; 1987 May; 175(5):309-10. PubMed ID: 3572384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.